enquiry@pharmascroll.com
Mail Us
-
FDA approves Alembic’s generic drug for Major Depressive Disorder
- June 12, 2018
- Posted by: Pharmascroll
No CommentsAlembic Pharmaceuticals, a vertically integrated Research and Development Pharmaceutical company, announced on June 11th 2018, that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed
-
Esketamine displays positive Ph 3 trial outcomes for Depression
- June 3, 2018
- Posted by: Pharmascroll
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from two long-term Phase 3 clinical studies of the investigational compound esketamine nasal spray in patients with treatment-resistant depression. These studies, one that showed a delayed time to relapse and a second that provided evidence of safe long-term use of esketamine, were presented at the
-
Allergan acquires depression compound from Aptinyx
- May 24, 2018
- Posted by: Pharmascroll
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator. Aptinyx discovered AGN-241751 utilizing its proprietary chemistry platform and the compound was selected for further development by Allergan under its ongoing
-
33 percent more people suffer from Depression as compared to 2013, new research finds
- May 11, 2018
- Posted by: Pharmascroll
In this report, Blue Cross Blue Shield Association examined diagnosed major depressive disorder (major depression) using the breadth and depth of data available through the Blue Cross Blue Shield Health Index. According to the BCBS Health Index, major depression is the second most impactful condition on overall health for commercially insured Americans, second to hypertension
-
Esketamine improves outcomes in Treatment-Resistant Depression patients, new Phase 3 data shows
- May 8, 2018
- Posted by: Pharmascroll
Study in adults with treatment-resistant depression marks the first time an antidepressant has achieved superiority in a clinical trial for major depressive disorder that included a newly initiated oral antidepressant in both the control and placebo groups Study in elderly patients is the first large clinical trial in treatment-resistant depression in this population Results demonstrate
-
NDA submitted for Brexanolone in Postpartum Depression by Sage Therapeutics
- April 24, 2018
- Posted by: Pharmascroll
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, an intravenous formulation of brexanolone (SAGE-547), for the treatment of postpartum depression
-
Intranasal Esketamine improves Depression symptoms as per latest clinical trial results
- April 21, 2018
- Posted by: Pharmascroll
As per the recent trial results published in The American Journal of Psychiatry, intranasal esketamine, the nasal-spray form of the club drug ketamine, has had a positive impact and led to rapid improvement in depressive symptoms, including some measures of suicidal ideation, among depressed patients at imminent risk for suicide. The authors of the trial